KR101814558B1 - 염증성 장 질환을 예방 및 치료하기 위한 약물 제조에 있어 살모넬라 플라젤린 유도체의 용도 - Google Patents

염증성 장 질환을 예방 및 치료하기 위한 약물 제조에 있어 살모넬라 플라젤린 유도체의 용도 Download PDF

Info

Publication number
KR101814558B1
KR101814558B1 KR1020147002932A KR20147002932A KR101814558B1 KR 101814558 B1 KR101814558 B1 KR 101814558B1 KR 1020147002932 A KR1020147002932 A KR 1020147002932A KR 20147002932 A KR20147002932 A KR 20147002932A KR 101814558 B1 KR101814558 B1 KR 101814558B1
Authority
KR
South Korea
Prior art keywords
czlc331
protein
tat
treatment
ibd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147002932A
Other languages
English (en)
Korean (ko)
Other versions
KR20140054018A (ko
Inventor
청강 장
쥔화이 리
양 쉬
융훙 우
웨이광 리
옌춘 장
옌 가오
즈훼이 리
Original Assignee
수저우 시스케이프 바이오메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드
인스티튜트 오브 레디에이션 메디신, 아카데미 오브 밀리터리 메디칼 사이언티시즈 오브 더 피엘에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수저우 시스케이프 바이오메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드, 인스티튜트 오브 레디에이션 메디신, 아카데미 오브 밀리터리 메디칼 사이언티시즈 오브 더 피엘에이 filed Critical 수저우 시스케이프 바이오메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드
Publication of KR20140054018A publication Critical patent/KR20140054018A/ko
Application granted granted Critical
Publication of KR101814558B1 publication Critical patent/KR101814558B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147002932A 2011-07-05 2012-01-19 염증성 장 질환을 예방 및 치료하기 위한 약물 제조에 있어 살모넬라 플라젤린 유도체의 용도 Expired - Fee Related KR101814558B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110186065 2011-07-05
CN201110186065.6 2011-07-05
PCT/CN2012/000097 WO2013004069A1 (zh) 2011-07-05 2012-01-19 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用

Publications (2)

Publication Number Publication Date
KR20140054018A KR20140054018A (ko) 2014-05-08
KR101814558B1 true KR101814558B1 (ko) 2018-01-30

Family

ID=47436474

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147002932A Expired - Fee Related KR101814558B1 (ko) 2011-07-05 2012-01-19 염증성 장 질환을 예방 및 치료하기 위한 약물 제조에 있어 살모넬라 플라젤린 유도체의 용도

Country Status (8)

Country Link
US (2) US9259453B2 (https=)
EP (1) EP2730287B1 (https=)
JP (1) JP5876930B2 (https=)
KR (1) KR101814558B1 (https=)
CN (1) CN102861317B (https=)
AU (1) AU2012278744B2 (https=)
CA (1) CA2840924A1 (https=)
WO (1) WO2013004069A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273198B2 (en) 2017-05-04 2022-03-15 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US10402165B2 (en) 2017-08-30 2019-09-03 Gsi Technology Inc. Concurrent multi-bit adder
CN108159397A (zh) * 2018-02-28 2018-06-15 中南大学湘雅三医院 一种肠罗斯氏菌重组鞭毛蛋白在制备防治炎症性肠病药物中的应用
CN108404113A (zh) * 2018-05-16 2018-08-17 中国人民解放军军事科学院军事医学研究院 用于抗辐射损伤的口服辐抗肽药物组合物
US20220218786A1 (en) * 2019-03-28 2022-07-14 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition for preventing or treating graft-versus-host disease comprising tlr5 agonist derived from flagellin as effective component
CN110420317B (zh) * 2019-07-25 2022-11-22 中国人民解放军军事科学院军事医学研究院 Cblb502蛋白在防治创伤后应激障碍中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050073865A (ko) * 2004-01-12 2005-07-18 대한민국(전남대학교총장) 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제
EP2374474A1 (en) * 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
BRPI0911604A2 (pt) * 2008-04-25 2015-12-15 Inst Systems Biology vacinas de polipeptídeo de flagelina
CN101411872A (zh) 2008-11-25 2009-04-22 中国科学院武汉病毒研究所 预防龋齿的疫苗试剂盒及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Inflammatory bowel diseases, Vol. 15, pages 789-795 (2009)
Inflammatory bowel diseases, Vol. 16, pages 1583-1597 (2010)

Also Published As

Publication number Publication date
US9259453B2 (en) 2016-02-16
EP2730287B1 (en) 2018-02-28
CA2840924A1 (en) 2013-01-10
WO2013004069A1 (zh) 2013-01-10
US20140248348A1 (en) 2014-09-04
JP5876930B2 (ja) 2016-03-02
CN102861317B (zh) 2014-07-02
AU2012278744B2 (en) 2016-11-24
EP2730287A4 (en) 2015-03-18
EP2730287A1 (en) 2014-05-14
US20160060305A1 (en) 2016-03-03
KR20140054018A (ko) 2014-05-08
US9630999B2 (en) 2017-04-25
AU2012278744A1 (en) 2014-02-20
NZ619871A (en) 2016-02-26
JP2014522819A (ja) 2014-09-08
CN102861317A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
KR101814558B1 (ko) 염증성 장 질환을 예방 및 치료하기 위한 약물 제조에 있어 살모넬라 플라젤린 유도체의 용도
JP7590724B2 (ja) 炎症性腸疾患の治療薬
Liu et al. Anti‐high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats
US10654895B2 (en) Polypeptide, DNA molecule encoding the polypeptide, vector, preparation method and use
AU2015268101B2 (en) Modulation of cellular stress
CN112691114B (zh) 苦瓜多糖在制备用于治疗溃疡性结肠炎药物中的应用及其药物制剂
BR112018009437A2 (en) control of cellular oxeduction levels
CN104382863B (zh) 一种禽用伊维菌素泡腾颗粒
EP3773686B1 (en) Alkaline phosphatase agents for treatment of radiation disorders
CN106543287A (zh) 构象表位疫苗和应用
CN113755580A (zh) 一种治疗和/或缓解淋巴水肿的药物干预靶点及其应用
CN118285504B (zh) 具有菌源二肽基肽酶-4抑制活性的植物提取物及其应用
NZ619871B2 (en) Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases
CN112076189B (zh) 一种酰胺化合物在制备治疗脓毒症药物中的应用
RU2812805C1 (ru) Способ ингибирования сигнального пути PD-1/PD-L1 в раковых клетках мочевого пузыря
JP2011518212A (ja) 自己免疫疾患の治療における、ｐａｔノナペプチドの使用
Geng et al. Nodakenin ameliorated TNBS-induced experimental colitis in mice by inhibiting intestinal epithelial cell pyroptosis
CN121991171A (zh) 一种预防和治疗溃疡性结肠炎的红小豆多肽及其应用
US20240189389A1 (en) Drug with prolonged analgesic action
CN118184736A (zh) 活性肽、含有活性肽的组合物及其应用
CN121592743A (zh) 一种制备海马小肽组合物的方法、组合物及应用
CN115844876A (zh) 一种防治类风湿关节炎和/或骨关节炎的药物及应用
Class et al. Patent application title: Antagonists of the Interleukin-1 Receptor Inventors: Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK) Assignees: SERODUS ASA

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20201228

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201228